Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Medplus Health Services's Debt-to-EBITDA or its related term are showing as below:
NSE:MEDPLUS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.08 Med: 2.62 Max: 3.31
Current: 2.08
During the past 8 years, the highest Debt-to-EBITDA Ratio of Medplus Health Services was 3.31. The lowest was 2.08. And the median was 2.62.
NSE:MEDPLUS's Debt-to-EBITDA is ranked better than 51.88% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs NSE:MEDPLUS: 2.08
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Medplus Health Services Debt-to-EBITDA Related Terms
Medplus Health Services Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medplus Health Services Debt-to-EBITDA Competitor Comparison
For the Pharmaceutical Retailers subindustry, Medplus Health Services's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medplus Health Services Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medplus Health Services's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medplus Health Services's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Medplus Health Services (NSE:MEDPLUS) has a Debt-to-EBITDA of 0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medplus Health Services. Over the past decade, Medplus Health Services' Debt-to-EBITDA has ranged from 2.08 to 3.31. According to the industry distribution chart, Medplus Health Services ranks #230 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 48.1%.
Is Medplus Health Services' Debt-to-EBITDA too high?
Medplus Health Services' current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 2.08 to a high of 3.31. Based on the distribution chart, Medplus Health Services ranks #230 out of 478 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Medplus Health Services has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medplus Health Services' Debt-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Medplus Health Services ranks #230 out of 478 companies for Debt-to-EBITDA. This puts Medplus Health Services in the upper half of its industry. The industry median Debt-to-EBITDA is 2.20. Historically, Medplus Health Services' own Debt-to-EBITDA has ranged from 2.08 to 3.31 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medplus Health Services. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medplus Health Services's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medplus Health Services stock overvalued right now?
Based on GuruFocus' analysis, Medplus Health Services (NSE:MEDPLUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹968.42, compared to a current price of ₹649.30 — trading 33% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Medplus Health Services' overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Medplus Health Services (NSE:MEDPLUS), the current Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medplus Health Services (NSE:MEDPLUS) Overvalued in 2026?
Based on GuruFocus' analysis, Medplus Health Services stock appears to be undervalued.
The current stock price of ₹649.30 is trading 33% below its estimated GF Value™ of ₹968.42.
GuruFocus considers Medplus Health Services to be Significantly Undervalued.
Key valuation signals for NSE:MEDPLUS:
Debt-to-EBITDA: 0.00
GF Value™: ₹968.42 vs. price of ₹649.30 (33% below fair value)
No single metric tells the full story. See the NSE:MEDPLUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medplus Health Services Ltd is a pharmacy retailer. It offers pharmaceutical and wellness products such as medicines, vitamins, medical devices, test kits, and others. The company also offers an omnichannel platform wherein customers can purchase products through stores, place orders over the telephone, online orders, and a Click and Pick facility. Its operating segments include Retail, Diagnostics, and Others.
76GF Score
Get the complete analysis for NSE:MEDPLUS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDPLUS has been successfully added to your 
